MAPT and Alzheimer disease: MCC950 effectively blocks the activation of the NLRP3 inflammasome induced by Aβ or Tau, preventing the cleavage and release of caspase-1 and IL-1β, reducing Aβ deposition, and improving memory deficits and other symptoms in the APP/PS1 model of AD.